Market Place
Sourcing Support
Sol-Gel Reports Q3 2024 Results, Corporate Update
15 Nov 2024 //
GLOBENEWSWIRE
Sol-Gel Reports Q2 2024 Results And Provides Corporate Updates
17 Aug 2024 //
GLOBENEWSWIRE
Sol-Gel Reports Q2 2024 Results, Provides Corporate Updates
16 Aug 2024 //
GLOBENEWSWIRE
Sol-Gel Signs Six Deals For TWYNEO And EPSOLAY In Europe And S. Africa
25 Jul 2024 //
GLOBENEWSWIRE
Sol-Gel Technologies Announces Management Realignment
15 Jul 2024 //
GLOBENEWSWIRE
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
28 May 2024 //
GLOBENEWSWIRE
Sol-Gel Reports Q1 2024 Financials, Corporate Updates
20 May 2024 //
GLOBENEWSWIRE
Sol-Gel, Beimei Announce TWYNEO Commercialization Deal
16 May 2024 //
GLOBENEWSWIRE
Sol-Gel`s Collaboration Partner File ANDA Drug Product Generic to Zoryve® Cream
01 Apr 2024 //
GLOBENEWSWIRE
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
13 Mar 2024 //
GLOBENEWSWIRE
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
30 Nov 2023 //
GLOBENEWSWIRE
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome
28 Nov 2023 //
GLOBENEWSWIRE
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Sol-Gel to Participate in the H.C. Wainwright 25th Annual Global Conference
30 Aug 2023 //
GLOBENEWSWIRE
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Sol-Gel and Searchlight Pharma Announce Licensing Agreements
06 Jun 2023 //
GLOBENEWSWIRE
Sol-Gel Technologies Reports First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
Sol-Gel to Present at Wainwright Autoimmune & Inflammatory Disease Conference
20 Mar 2023 //
GLOBENEWSWIRE
Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
10 Mar 2023 //
GLOBENEWSWIRE
BridgeBio company sells off rare disease candidate to Galderma partner
28 Jan 2023 //
ENDPTS
Sol-Gel Acquires Patidegib, a PIII, FDA Orphan Product Candidate
27 Jan 2023 //
GLOBENEWSWIRE
Sol-Gel Announces Aggregate $22.8M Concurrent Registered Placement Offerings
27 Jan 2023 //
GLOBENEWSWIRE
Sol-Gel Technologies Reports 3Q 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Sol-Gel Technologies Appoints Michael Glezin VP, Business Development
03 Oct 2022 //
GLOBENEWSWIRE
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Sol-Gel Technologies to Participate in the 2022 Jefferies Conference
01 Jun 2022 //
GLOBENEWSWIRE
Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Conference
17 May 2022 //
GLOBENEWSWIRE
Sol-Gel Technologies Reports First Quarter 2022 Financial Results
13 May 2022 //
GLOBENEWSWIRE
Sol-Gel gets FDA approval for encapsulated skin disease drug
27 Apr 2022 //
FIERCEPHARMA
Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
25 Apr 2022 //
GLOBENEWSWIRE
Sol-Gel Technologies Announces the Commercial Availability of TWYNEO
14 Apr 2022 //
GLOBENEWSWIRE
Sol-Gel Technologies Reports Full Year 2021 Financial Results
30 Mar 2022 //
GLOBENEWSWIRE
Sol-Gel Announces U.S. Commercial Partner Galderma to Promote TWYNEO at AAD
25 Mar 2022 //
GLOBENEWSWIRE
Sol-Gel Technologies to Participate Upcoming LifeSci Partners Corporate Access
22 Dec 2021 //
GLOBENEWSWIRE
Sol-Gel Technologies Announces Positive Update Related to FDA Review of EPSOLAY®
21 Dec 2021 //
GLOBENEWSWIRE
Sol-Gel Reports Q3 2021 Financial Results and Highlights Recent Developments
11 Nov 2021 //
GLOBENEWSWIRE
Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
09 Nov 2021 //
GLOBENEWSWIRE
Sol-Gel Announces Sale of Generic Dermatology to Partner Padagis for $21 M
04 Nov 2021 //
YAHOO
Sol-Gel to Partner Padagis for $21M
04 Nov 2021 //
GLOBENEWSWIRE
Sol-Gel Technologies to Present at Upcoming Cantor Virtual Conference
22 Sep 2021 //
GLOBENEWSWIRE
Sol-Gel and Galderma Announce Exclusive Licenses for EPSOLAY® and TWYNEO®
28 Jun 2021 //
BUSINESSWIRE
Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®
27 Apr 2021 //
GLOBENEWSWIRE
Sol-Gel Technologies Announces FDA Acceptance for Filing of NDA for Twyneo®
07 Dec 2020 //
GLOBENEWSWIRE
Sol-Gel Announces FDA Acceptance for New Drug Application for Epsolay
10 Sep 2020 //
BIOSPACE
Sol-Gel Collaboration Partner Filed Paragraph IV Certification for Duobrii
03 Sep 2020 //
BIOSPACE
Sol-Gel Technologies Announces Agreements with Perrigo Company
29 Jun 2020 //
GLOBENEWSWIRE
Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment
13 Apr 2020 //
GLOBENEWSWIRE
Sol-Gel Announces +ve Topline Results from Open-Label, Safety Study of Epsolay
13 Feb 2020 //
GLOBENEWSWIRE
Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in (PPK)
02 Jan 2020 //
GLOBENEWSWIRE
